Skip to content

LiverSleep: A Behavioral Sleep Intervention for Patients With Cirrhosis and Insomnia

LiverSleep: An Adapted Telehealth-Delivered Cognitive Behavioral Therapy Intervention for Patients With Cirrhosis and Insomnia

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07417163
Enrollment
11
Registered
2026-02-18
Start date
2026-02-26
Completion date
2026-07-09
Last updated
2026-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis, Insomnia

Brief summary

This is a pilot trial to test the feasibility and acceptability of a virtual cognitive behavioral program for insomnia for patients with cirrhosis.

Interventions

BEHAVIORALAdapted Virtual Insomnia Program

4 sessions (approximately 45 min/each, weekly) delivered virtually. Sessions are modeled after a published, evidence-based CBT-I protocol and adapted to target needs and preferences of patients with cirrhosis.

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult (≥ 18 years) patients with cirrhosis (either compensated or decompensated) receiving ambulatory care at the MGH Liver Clinic or MGH Liver Transplant Evaluation Clinic 2. Have the ability to communicate in English 3. Have at least mild insomnia (ISI score ≥8) and report sleep difficulty, defined as ≥ 30 min to fall asleep or spending at least 30 min awake during the night

Exclusion criteria

1. Uncontrolled neuropsychiatric disorders such as severe depression, schizophrenia, or suicidal ideation which prohibits their ability to provide informed consent. 2. Cognitive impairment, which we will screen for using the simplified Animal Naming Test 3. Current alcohol misuse 4. Diagnosis of obstructive sleep apnea that is untreated or high-risk for obstructive sleep apnea 5. Severe restless leg syndrome 6. Those with night/rotating shift work

Design outcomes

Primary

MeasureTime frameDescription
Feasibility: Enrollment rate of those screened and eligibleBaseline to Week 4Percent of those screened and eligible who enroll (i.e., sign consent and complete baseline). Reasons for ineligibility, refusal, or drop out, will also be measured along with session attendance.

Secondary

MeasureTime frameDescription
Acceptability: 5 item measure of enjoyableness, convenience, helpfulness, odds of future use, and overall satisfactionBaseline to Week 8 (4 weeks post-intervention)Participants will be asked to rate the enjoyableness, convenience, helpfulness, odds of future use, and overall satisfaction (1=very low to 5=very high) of the program in exit interviews, which will use open-ended questions and response probes to explicate each rating

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 24, 2026